Soligenix's ThermoVax able to stabilize vaccines up to one year

Soligenix, a Princeton, New Jersey-based clinical stage biopharmaceutical company, announced positive results on Wednesday for a study involving its vaccine heat stabilization technology, ThermoVax.

According to Soligenix, recent studies demonstrated the potential for heat-sensitive vaccines formulated using ThermoVax to withstand temperatures of higher than 104 degrees Fahrenheit for up to one year. The studies follow previous evaluations that indicated the retention of potency for at least six months at temperatures as high as 104 degrees Fahrenheit.

The recent studies used a combination of sensitive techniques to evaluate the structure of Soligenix's ricin toxin vaccine, RiVax, and the resulting immunogenicity. The studies found the vaccine retained original levels of potency after one year of storage at 104 degrees Fahrenheit.

Soligenix also previously reported that its proprietary anthrax vaccine, VeloThrax, was able to maintain its full potency after being exposed to temperatures as high as 158 degrees Fahrenheit.

"The success attained thus far with both ThermoVax formulated RiVax and ThermoVax formulated VeloThrax further demonstrates the robustness and broad applicability of the ThermoVax technology," Christopher Schaber, the president and CEO of Soligenix, said. "We believe that ThermoVax could be applied to a wide variety of vaccines and adjuvants to eliminate the need for refrigeration and cold chain distribution."

The research and development of Soligenix is being supported by a $9.4 million grant from the National Institute of Allergy and Infectious Disease for biodefense vaccines to prevent anthrax and ricin toxin exposure.

"We believe ThermoVax is a significant step forward in vaccine technology and has the potential to lead to major cost savings in the distribution and storage of currently marketed vaccines and could further facilitate their use in the developing world," Schaber said. "We remain excited about the potential utility of the ThermoVax platform and have initiated discussions with a number of vaccine companies and non-profit organizations regarding the potential for collaboration on heat stable versions of their vaccine candidates."